Long-term assessment of quality of life in the Intergroup Exemestane Study: 5 years post-randomisation
British Journal of Cancer2012Vol. 106(6), pp. 1062–1067
Citations Over TimeTop 14% of 2012 papers
Abstract
Clinical benefits of switching to exemestane are accompanied by good overall QoL. Although some symptoms persist, the majority of endocrine symptoms improve after treatment completion.
Related Papers
- → Aromatase inhibitors in the breast cancer clinic: focus on exemestane(2014)62 cited
- A review of the use of exemestane in early breast cancer.(2009)
- → Comparison of the effects of the irreversible aromatase inhibitor exemestane with atamestane and MDL 18962 in rats with DMBA-induced mammary tumours(1991)37 cited
- → Exemestane improves survival compared with megoestrol acetate in postmenopausal patients with advanced breast cancer who have failed on tamoxifen(2000)29 cited
- Five years of adjuvant exemestane offers no benefit over sequential tamoxifen-exemestane(2009)